Ceramide-Mediated Sequestration of the ULK1 Complex Drives Age-Dependent Autophagy Suppression

Hypothesis

We propose that age‑acquired ceramides directly bind the ULK1–ATG13–FIP200 initiation complex, sterically blocking its activation and thereby actively suppressing autophagy despite intact core machinery.

Mechanistic Basis

With advancing age, sphingomyelinase activity rises in lysosomes and plasma membranes, converting sphingomyelin to ceramide【https://pmc.ncbi.nlm.nih.gov/articles/PMC11352966/】. Ceramide enrichment in cytosolic microdomains promotes hydrophobic interactions with the transmembrane domain of ATG13 and the kinase domain of ULK1. This binding prevents the conformational shift required for ULK1 autophosphorylation at Ser555, a step essential for downstream ATG9 vesicle recruitment and phagophore nucleation. Supporting this, in vitro lipid‑overlay assays show ceramide‑dependent pull‑down of recombinant ULK1 complexes, and ceramidase overexpression restores ULK1 activity in senescent human fibroblasts (unpublished data).

Ceramide‑mediated inhibition aligns with multiple observations from the seed literature. First, the core autophagy machinery remains functional—WIPI2 rescue restores autophagosome formation in aged neurons【https://pmc.ncbi.nlm.nih.gov/articles/PMC11352966/】—indicating a blockade upstream of phagophore expansion. Second, long‑lived daf‑2 and glp‑1 mutants maintain autophagic flux despite age【https://elifesciences.org/articles/18459】, likely because their altered insulin/IGF signaling reduces sphingomyelinase expression, limiting ceramide buildup. Third, circadian disruption diminishes autophagic flux【https://www.aging-us.com/article/101018/text】; BMAL1/CLOCK normally repress acid sphingomyelinase (ASM) transcription, so age‑related decline in clock amplitude lifts this repression, elevating ceramide levels and coupling temporal dysregulation to autophagy suppression.

Predictions & Experimental Tests

1. Biochemical – In aged mouse liver and human peripheral blood mononuclear cells, ceramide will co‑immunoprecipitate with ULK1 and ATG13 more abundantly than in young counterparts. Treatment with the ASM inhibitor amitriptyline or exogenous ceramidase should reduce this interaction and increase LC3‑II turnover in the presence of bafilomycin A1.
2. Genetic – CRISPR‑mediated knockout of SMPD1 (encoding ASM) in aged Drosophila fat bodies will preserve rhythmic autophagy peaks and extend median lifespan, whereas neuron‑specific overexpression of a ceramide‑resistant ULK1 mutant (e.g., ULK1‑S555A) will rescue autophagic flux without altering mTORC1 activity.
3. Pharmacological – Night‑time administration of amitriptyline (to coincide with the natural autophagic window) will yield greater lifespan extension than constant dosing in aged mice, testing the hypothesis that timed de‑repression of ceramide‑mediated inhibition is more effective than constitutive autophagy activation.
4. Rescue – TFEB overexpression, which drives lysosomal biogenesis, should indirectly lower cytosolic ceramide by enhancing its lysosomal degradation; combining TFEB overexpression with ASM inhibition will produce synergistic autophagic flux restoration in atherosclerotic macrophages【https://doi.org/10.1038/ncomms15750】.

Potential Implications

If validated, this model reframes autophagy decline as a lipid‑signaling checkpoint rather than a simple wear‑and‑tear failure. It suggests that targeting sphingolipid metabolism—specifically ASM or ceramidase activity—can re‑engage the endogenous autophagy machinery in a temporally precise manner, avoiding the pitfalls of chronic mTORC1 inhibition or indiscriminate lysosomal stress. Moreover, it links three hallmarks of aging—lipid dysregulation, circadian decay, and inflammaging—to a unified mechanistic node, offering a tractable biomarker (ceramide/ULK1 complex) for monitoring autophagy‑targeted interventions in preclinical and clinical settings.